Literature DB >> 1220978

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.

G Rivera, T Avery, D W Roberts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1220978     DOI： 10.1016/0014-2964(75)90099-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  21 in total

1.  Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.

Authors:  R Liang; E Chiu; T K Chan; D Todd
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

Authors:  P B Jensen; H Roed; T Skovsgaard; E Friche; L Vindeløv; H H Hansen; M Spang-Thomsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  VM26 therapy in children with drug-refractory lymphocytic leukemia.

Authors:  G Rivera; G V Dahl; S B Murphy; W P Bowman; R J Aur; T L Avery; J V Simone
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues.

Authors:  J D Hainsworth
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 6.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 7.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  High-dose ara-C and etoposide in refractory or relapsing acute leukemia.

Authors:  M Freund; H Link; H Diedrich; S LeBlanc; H J Wilke; H Poliwoda
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.

Authors:  B L Powell; H B Muss; R L Capizzi; M E Caponera; D R White; P J Zekan; J N Atkins; D V Jackson; F Richards; J B Craig
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.